DRD2 and type 2 diabetes mellitus: Moreover, a dopamine receptor D2 (DRD2) agonist, bromocriptine, has recently been approved for the treatment of T2D in the USA, with positive effects on glucose tolerance, insulin sensitivity, and circulating lipids [6–8].